NCT06126562View on ClinicalTrials.gov

A Pharmacokinetic Study of Lanifibranor in Healthy Adult Chinese Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

October 31, 2023

Primary Completion Date

November 28, 2023

Study Completion Date

December 15, 2023

Conditions
Pharmacokinetic
Interventions
DRUG

Lanifibranor

Lanifibranor is a pan-peroxisome proliferator-activated receptor (PPAR) agonist.

Trial Locations (1)

130021

The First Hospital of Jilin University, Changchun

Sponsors
All Listed Sponsors
lead

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

INDUSTRY